three out of five with vasculitis, five out of 14 with monoclonal peak. Complement level at diagnosis had a prognostic significance in our group of patients. Median survival was 94 months in the patients presenting with normal C3 and C4 values compared to 67 months with low serum complement.
In conclusion, we did not find a correlation between C3 and C4 level and clinical stage of CLL. However, our data suggest that hypocomplementemia correlates with lymphocyte activation and differentiation stage in chronic lymphoproliferative diseases. Low serum complement level in CLL and PLL is associated with autoimmune features and poor prognosis.
The complement system in chronic B cell lymphoproliferative disorders

TO THE EDITOR
Shvidel et al report a study of the C3 and C4 serum complement levels in chronic lymphoproliferative diseases of the B cell type. They found a correlation between hypocomplementemia lymphocyte activation and differentiation stage, the presence of auto immune features and prognosis, but not with the clinical stage of the disease. Their observations tend to confirm the importance of the complement system in B cell lymphoproliferative disorders. Our study 1 of the complement system in chronic lymphocyte leukemia (CLL), in which we checked all the serum component levels of the three main pathways, showed a correlation between hypocomplementemia and predisposition to auto immune features in CLL patients, but also with the stage of the disease and the tendency to develop severe life-threatening infections.
A similarly pathological complement system was found among first degree relatives of CLL patients, thus raising the hypothesis of a hereditary background for hypocomplementemia in CLL. We are currently conducting a study of the complement system, including activation of the three main pathways, in a cohort of multiple myeloma patients. This study could improve our understanding of the role of the complement system in chronic lymphoproliferative disorders and its correlation with lymphocyte activation and differentiation stage.
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